JPRN-UMIN000017446招募中未知
tility study of PET imaging with 64Cu-DOTA labeled antibody probes against HER2 and EGFR - Cu-DOTA molecular imaging
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 25years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Severe drug hypersensitivity 2. Ischemic heart disease, cardiomyopathy, congestive heart failure and uncontrolled arrhythmia 3. Active infectious disease, interstitial pneumonia and pulmonary fibrosis 4. Organ insufficiency (bone marrow, liver and kidney) 5. Active synchronous double cancer 6. Pregnancy and lactating (including possibility and intention) 7. Decision of the physician
研究者
相似试验
招募中
不适用
Feasibility study of PET Imaging with 64Cu-DOTA-trastuzumab in HER2 positive breast cancer1. Patients with invasive ductal carcinoma of breast. 2. HER2 positive (IHC 3+>or FISH positive) breast cancer 3. Currently taking or about to commence treatment with trastuzumab or trastumab based chemotherapy 4. Age: >20 years, <75 years 5. ECOG Performance Score 0 or 1. 6. Good main organ function 7. Capability to be received PET scan. 8. Signed informed consentJPRN-UMIN000004170ational Cancer Center Hospital40
进行中（未招募）
1 期
Combined 64Cu-DOTATATE and 18F-FDG PET/CT Imaging in Patients with Neuroendocrine Tumorseuroendocrine neoplasmsMedDRA version: 21.0Level: LLTClassification code 10062476Term: Neuroendocrine tumorSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10057270Term: Neuroendocrine carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: LLTClassification code 10068916Term: Pancreatic neuroendocrine tumor metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10071542Term: Neuroendocrine carcinoma metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10077560Term: Gastroenteropancreatic neuroendocrine tumor diseaseSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: LLTClassification code 10067518Term: Pancreatic neuroendocrine tumorSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 24.1Level: LLTClassification code 10085846Term: Duodenal neuroendocrine tumorSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 24.1Level: LLTClassification code 10085958Term: Small intestine neuroendocrine tumorSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2021-005919-30-DKDepartment of Clinical Physiology and Nuclear Medicine, Rigshospitalet200
未知
不适用
64Cu-DOTA-nivolumab PET imaging in patients with malignant melanoma or non-small cell lung cancer.nresectable or metastatic malignant melanoma,unresectable or metastatic non small cell lung cancerJPRN-UMIN000026658ational Cancer Center Hospital, Tokyo, Japan50
进行中（未招募）
1 期
se of the diagnostic PET with 64CuCl2 in order to select patients, in which a disease relapse is shown after prostate surgical removal, to be successfully treated to radiation therapy on the prostate bedcancer on the prostatic bedMedDRA version: 20.0Level: PTClassification code 10060862Term: Prostate cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-004332-11-ITSPARKLE SR138
招募中
不适用
PET imaging of breast cancer using 64Cu-DOTA-Trastuzumab for evaluating HER2 expression: Investigator Initiated TrialsKCT0002791Korea Cancer Center Hospital30